NCT06512506 Prospective Cohort Study of Arthroscopic Treatment of Hip Dysplasia
| NCT ID | NCT06512506 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Developmental Dysplasia of the Hip |
| Study Type | OBSERVATIONAL |
| Enrollment | 47 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 47 participants in total. It began in 2022-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
On the basis of the database established in the previous stage, a cohort analysis was conducted on patients with BDDH complicated by hip arthroscopy for minimally invasive treatment of glenoid and lip injury, according to which the indications of minimally invasive surgery for BDDH patients were optimized and surgical measures were improved. Achieve accurate and rapid repair, rehabilitation and functional recovery, serve national fitness, and treat people's injuries
Eligibility Criteria
Inclusion Criteria: \- Diagnosis of borderline hip dysplasia with glenolabial injury. Exclusion Criteria: \-
Contact & Investigator
Jianquan J Wang, M.D.
STUDY CHAIR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT06512506 clinical trial?
This trial is open to participants of all sexes, studying Developmental Dysplasia of the Hip. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06512506 currently recruiting?
Yes, NCT06512506 is actively recruiting participants. Contact the research team at wjqsportsmed@163.com for enrollment information.
Where is the NCT06512506 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06512506 clinical trial?
NCT06512506 is sponsored by Peking University Third Hospital. The principal investigator is Jianquan J Wang, M.D. at Peking University Third Hospital. The trial plans to enroll 47 participants.